For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 4,779 | 4,877* | 5,370 | 5,502 |
| General and administrative | 5,091 | 4,828* | 3,881 | 3,538 |
| Total operating expenses | 9,870 | 9,704 | 9,251 | 9,040 |
| Operating loss | -9,870 | -9,704* | -9,251 | -9,040 |
| Impairment charge on investment in equity securities | - | 0* | 0 | - |
| Interest income | 309 | 555* | 570 | 645 |
| Other expense, net | -28 | 53* | -11 | -28 |
| Loss before income taxes | -9,589 | -9,097* | -8,692 | -8,423 |
| Income tax benefit | 0 | 0* | 0 | 0 |
| Net loss | -9,589 | -9,097 | -8,692 | -8,423 |
| Basic EPS | -1.11 | 0.039 | -0.07 | -0.07 |
| Diluted EPS | -1.11 | 0.039 | -0.07 | -0.07 |
| Basic Average Shares | 8,622,289 | -232,507,886 | 129,171,424 | 129,170,425 |
| Diluted Average Shares | 8,622,289 | -232,507,886 | 129,171,424 | 129,170,425 |
ATOSSA THERAPEUTICS, INC. (ATOS)
ATOSSA THERAPEUTICS, INC. (ATOS)